Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.254 [Categoria DeCS]
Referências encontradas : 69732 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6974 ir para página                         

  1 / 69732 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381765
[Au] Autor:Haralambieva IH; Kennedy RB; Simon WL; Goergen KM; Grill DE; Ovsyannikova IG; Poland GA
[Ad] Endereço:Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America.
[Ti] Título:Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination.
[So] Source:PLoS One;13(1):e0191812, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: MicroRNAs are important mediators of post-transcriptional regulation of gene expression through RNA degradation and translational repression, and are emerging biomarkers of immune system activation/response after vaccination. METHODS: We performed Next Generation Sequencing (mRNA-Seq) of intracellular miRNAs in measles virus-stimulated B and CD4+ T cells from high and low antibody responders to measles vaccine. Negative binomial generalized estimating equation (GEE) models were used for miRNA assessment and the DIANA tool was used for gene/target prediction and pathway enrichment analysis. RESULTS: We identified a set of B cell-specific miRNAs (e.g., miR-151a-5p, miR-223, miR-29, miR-15a-5p, miR-199a-3p, miR-103a, and miR-15a/16 cluster) and biological processes/pathways, including regulation of adherens junction proteins, Fc-receptor signaling pathway, phosphatidylinositol-mediated signaling pathway, growth factor signaling pathway/pathways, transcriptional regulation, apoptosis and virus-related processes, significantly associated with neutralizing antibody titers after measles vaccination. No CD4+ T cell-specific miRNA expression differences between high and low antibody responders were found. CONCLUSION: Our study demonstrates that miRNA expression directly or indirectly influences humoral immunity to measles vaccination and suggests that B cell-specific miRNAs may serve as useful predictive biomarkers of vaccine humoral immune response.
[Mh] Termos MeSH primário: Anticorpos Antivirais/biossíntese
Linfócitos B/metabolismo
Vacina contra Sarampo/administração & dosagem
Sarampo/imunologia
MicroRNAs/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Linfócitos B/imunologia
Feminino
Seres Humanos
Lactente
Masculino
Vacina contra Sarampo/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Measles Vaccine); 0 (MicroRNAs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191812


  2 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377916
[Au] Autor:Tutykhina I; Esmagambetov I; Bagaev A; Pichugin A; Lysenko A; Shcherbinin D; Sedova E; Logunov D; Shmarov M; Ataullakhanov R; Naroditsky B; Gintsburg A
[Ad] Endereço:Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia.
[Ti] Título:Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.
[So] Source:PLoS One;13(1):e0191574, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To avoid outbreaks of influenza virus epidemics and pandemics among human populations, modern medicine requires the development of new universal vaccines that are able to provide protection from a wide range of influenza A virus strains. In the course of development of a universal vaccine, it is necessary to consider that immunity must be generated even against viruses from different hosts because new human epidemic virus strains have their origins in viruses of birds and other animals. We have enriched conserved viral proteins-nucleoprotein (NP) and matrix protein 2 (M2)-by B and T-cell epitopes not only human origin but also swine and avian origin. For this purpose, we analyzed M2 and NP sequences with respect to changes in the sequences of known T and B-cell epitopes and chose conserved and evolutionarily significant epitopes. Eventually, we found consensus sequences of M2 and NP that have the maximum quantity of epitopes that are 100% coincident with them. Consensus epitope-enriched amino acid sequences of M2 and NP proteins were included in a recombinant adenoviral vector. Immunization with Ad5-tet-M2NP induced strong CD8 and CD4 T cells responses, specific to each of the encoded antigens, i.e. M2 and NP. Eight months after immunization with Ad5-tet-M2NP, high numbers of M2- and NP-responding "effector memory" CD44posCD62neg T cells were found in the mouse spleens, which revealed a long-term T cell immune memory conferred by the immunization. In all, the challenge experiments showed an extraordinarily wide-ranging efficacy of protection by the Ad5-tet-M2NP vaccine, covering 5 different heterosubtypes of influenza A virus (2 human, 2 avian and 1 swine).
[Mh] Termos MeSH primário: Linfócitos B/imunologia
Epitopos/imunologia
Vírus da Influenza A/imunologia
Nucleoproteínas/imunologia
Linfócitos T/imunologia
Vacinação
Proteínas da Matriz Viral/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Epitopes); 0 (Nucleoproteins); 0 (Viral Matrix Proteins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191574


  3 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461066
[Au] Autor:Gilbert NL; Rotondo J; Shapiro J; Sherrard L; Fraser WD; Ward BJ
[Ad] Endereço:Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada; École de santé publique de l'Université de Montréal, Montreal, Canada. Electronic address: nicolas.gilbert@phac-aspc.gc.ca.
[Ti] Título:Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008-2011.
[So] Source:Vaccine;35(23):3050-3055, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n=1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5IU/mL, 5-10IU/mL, and ≥10IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08-16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45-10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07-6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Suscetibilidade a Doenças
Complicações Infecciosas na Gravidez/imunologia
Rubéola (Sarampo Alemão)/epidemiologia
Rubéola (Sarampo Alemão)/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Canadá/epidemiologia
Estudos de Coortes
Escolaridade
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Imunoglobulina G/sangue
Meia-Idade
Gravidez
Complicações Infecciosas na Gravidez/prevenção & controle
Complicações Infecciosas na Gravidez/virologia
Rubéola (Sarampo Alemão)/virologia
Síndrome da Rubéola Congênita/prevenção & controle
Estudos Soroepidemiológicos
Vacinação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Immunoglobulin G); 0 (rubella antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  4 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457675
[Au] Autor:Wichgers Schreur PJ; van Keulen L; Kant J; Kortekaas J
[Ad] Endereço:Department of Virology, Wageningen Bioveterinary Research, Lelystad, The Netherlands. Electronic address: paul.wichgersschreur@wur.nl.
[Ti] Título:Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
[So] Source:Vaccine;35(23):3123-3128, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Rift Valley fever virus (RVFV) causes severe and recurrent outbreaks on the African continent and the Arabian Peninsula and continues to expand its habitat. This mosquito-borne virus, belonging to the genus Phlebovirus of the family Bunyaviridae contains a tri-segmented negative-strand RNA genome. Previously, we developed four-segmented RVFV (RVFV-4s) variants by splitting the M-genome segment into two M-type segments each encoding one of the structural glycoproteins; Gn or Gc. Vaccination/challenge experiments with mice and lambs subsequently showed that RVFV-4s induces protective immunity against wild-type virus infection after a single administration. To demonstrate the unprecedented safety of RVFV-4s, we here report that the virus does not cause encephalitis after intranasal inoculation of mice. A study with pregnant ewes subsequently revealed that RVFV-4s does not cause viremia and does not cross the ovine placental barrier, as evidenced by the absence of teratogenic effects and virus in the blood and organs of the fetuses. Altogether, these results show that the RVFV-4s vaccine virus can be applied safely in pregnant ewes.
[Mh] Termos MeSH primário: Febre do Vale de Rift/prevenção & controle
Vírus da Febre do Vale do Rift/genética
Vírus da Febre do Vale do Rift/imunologia
Doenças dos Ovinos/prevenção & controle
Vacinas Virais/administração & dosagem
Vacinas Virais/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Encefalite Viral/etiologia
Encefalite Viral/veterinária
Feminino
Genoma Viral/genética
Genoma Viral/imunologia
Camundongos
Gravidez
Febre do Vale de Rift/virologia
Vírus da Febre do Vale do Rift/química
Ovinos
Carneiro Doméstico/imunologia
Teratogênios
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/efeitos adversos
Vacinas Atenuadas/imunologia
Vacinas Virais/imunologia
Viremia/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Teratogens); 0 (Vaccines, Attenuated); 0 (Viral Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  5 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457672
[Au] Autor:Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
[Ad] Endereço:Instituto Nacional de Salud Pública, Mexico. Electronic address: jdiaz@insp.mx.
[Ti] Título:Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
[So] Source:Vaccine;35(23):3116-3122, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:IMPORTANCE: In a previous study on booster vaccination, we reported that two aerosolized MMR vaccines were as safe and immunogenic as injectable vaccines containing the same antigens. We now present results of antibody persistence one year after immunization. OBJECTIVE: To assess the antibody persistence for measles, mumps, and rubella one year following booster immunization. METHODS: We performed clinical and serological follow-up of participants in a previous study of Mexican children aged 6-7years, in which participants were randomized to four groups receiving, by aerosolized or by injection, the MMR SII vaccine (Serum Institute of India), or the MMR II (Merck Sharp & Dhome). We evaluated the antibody persistence by PRN test for measles and by ELISA for rubella and mumps. The occurrence of clinical events was evaluated via periodic visits of a nurse team to children's schools and homes. RESULTS: Of the 260 initial participants, 241 completed one-year follow-up. There were only statistically significant differences in baseline seropositivity for mumps. One year after immunization, seropositivity in all groups was 100% for measles and rubella. The seropositivity rank for mumps was from 90.3% for the injected vaccine MMR II to 96.6% for vaccine MMR SII applied by aerosol; these differences were not statistically significant. With exception of the aerosolized vaccine MMR SII for the geometric mean titer (GMT) for measles, all study groups presented declination of GMT for the three viruses. The difference between the aerosolized vaccines MMR SII and MMR RII was statistically significant for mumps antibodies. Only mild clinical events were identified. CONCLUSION: Under conditions of no endemic transmission for measles and rubella, and of low circulation of mumps virus, school-aged children remained seropositive to the three viruses one year following booster immunization. The study was registered under CMN 2010-005 number at COFEPRIS (National Regulatory Authority).
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Imunização Secundária/métodos
Vírus do Sarampo/imunologia
Vacina contra Sarampo-Caxumba-Rubéola/imunologia
Vírus da Caxumba/imunologia
[Mh] Termos MeSH secundário: Aerossóis
Criança
Ensaio de Imunoadsorção Enzimática
Feminino
Seguimentos
Seres Humanos
Imunização Secundária/efeitos adversos
Índia/epidemiologia
Injeções
Masculino
Sarampo/epidemiologia
Sarampo/imunologia
Sarampo/prevenção & controle
Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem
Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos
Caxumba/epidemiologia
Caxumba/imunologia
Caxumba/prevenção & controle
Rubéola (Sarampo Alemão)/epidemiologia
Rubéola (Sarampo Alemão)/imunologia
Rubéola (Sarampo Alemão)/prevenção & controle
Vírus da Rubéola/imunologia
Estudos Soroepidemiológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aerosols); 0 (Antibodies, Viral); 0 (Measles-Mumps-Rubella Vaccine); 0 (rubella antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  6 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456531
[Au] Autor:Zhou Q; Wang Q; Shen H; Zhang Y; Zhang S; Li X; Acharya G
[Ad] Endereço:Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China; Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromso, Norway.
[Ti] Título:Rubella virus immunization status in preconception period among Chinese women of reproductive age: A nation-wide, cross-sectional study.
[So] Source:Vaccine;35(23):3076-3081, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Population-based studies on sero-epidemiology of Rubella in women before conception are lacking. The aim of this study was to investigate the sero-prevalence of Rubella in a nationwide survey among Chinese women planning to get pregnant within six months. METHODS: This population-based, cross-sectional, sero-survey of Rubella virus infection was a part of the National Free Preconception Health Examination Project covering all 31 provinces in Mainland China. Women intending to get pregnant within six months was enrolled between 2010 and 12. Information on demographic characteristics (age, residence status, race, education and occupation) and vaccination history was obtained by interviews. Rubella virus IgG sero-positivity was determined using venous blood samples. RESULTS: Of 2,120,131 women recruited to the study, Rubella virus IgG serology was available in 1,974,188 (99.3%). Participating women were of young age (median=28years), mostly engaged in agricultural activities (78%), and the majority (90%) had high school education or lower. The overall prevalence of Rubella virus IgG sero-positivity was 58.4% (1,161,129); geographical variation ranged from 92.5% in Jilin to 20.1% in Qinghai and 0.0% in Tibet. Only 4.6% (n=91,604) women reported to have had Rubella virus vaccination, and it varied from 18.6% (Guangdong) to 0.2% (Qinghai). Self-reported vaccination status did not correlate with Rubella virus IgG seropositivity. CONCLUSIONS: Prevalence of Rubella sero-positivity is low among Chinese women of reproductive age and there are significant regional differences. Over 40% of women being susceptible to Rubella in preconception period calls for a targeted screening and vaccination strategy.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Síndrome da Rubéola Congênita/prevenção & controle
Vacina contra Rubéola/imunologia
Vírus da Rubéola/imunologia
Estudos Soroepidemiológicos
[Mh] Termos MeSH secundário: Adulto
China
Estudos Transversais
Feminino
Seres Humanos
Gravidez
Reprodução
Vacina contra Rubéola/administração & dosagem
Vacinação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Rubella Vaccine); 0 (rubella antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  7 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455172
[Au] Autor:Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
[Ad] Endereço:Department of Pediatrics, Universidad del Valle and Centro de Estudios en Infectología Pediátrica, Cali, Colombia.
[Ti] Título:Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
[So] Source:Vaccine;35(28):3591-3597, 2017 06 16.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers. METHODS: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine. RESULTS: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME. CONCLUSION: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.
[Mh] Termos MeSH primário: Esquemas de Imunização
Imunogenicidade da Vacina
Vacina Antipólio de Vírus Inativado/efeitos adversos
Vacina Antipólio de Vírus Inativado/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Fezes/virologia
Feminino
Seres Humanos
Imunidade Humoral
Lactente
Intestinos/imunologia
América Latina
Masculino
Poliomielite/prevenção & controle
Vacina Antipólio de Vírus Inativado/administração & dosagem
Vacina Antipólio Oral/administração & dosagem
Vacina Antipólio Oral/efeitos adversos
Vacina Antipólio Oral/imunologia
Soroconversão
Vacinação
Eliminação de Partículas Virais
Organização Mundial da Saúde
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Poliovirus Vaccine, Inactivated); 0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  8 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455170
[Au] Autor:D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
[Ad] Endereço:Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland.
[Ti] Título:Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
[So] Source:Vaccine;35(22):2892-2901, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Simpler schedules for human papillomavirus (HPV) vaccine delivery could improve vaccine coverage and the effectiveness of cervical cancer prevention. The objective of this study was to systematically review evidence about the effects of two-dose compared with three-dose schedules for human papillomavirus (HPV) vaccine and to describe the uptake of two-dose HPV vaccination schedules globally. We searched PubMed, the Cochrane Central Registry of Controlled Trials, trials registers, and manufacturers' databases from their earliest date to February 2016. We selected randomised controlled trials and controlled clinical trials that directly compared HPV vaccine schedules with two or three doses. We extracted data on immunological and clinical outcomes and used meta-analysis where appropriate. We also described the use of two-dose HPV vaccine schedules globally. We screened 1464 items and included seven eligible noninferiority trials in 11 countries. In randomised comparisons amongst adolescent girls (three trials), geometric mean concentrations (GMC) of antibodies against HPV16 and HPV18 were non-inferior or inconclusive, up to 24months after a two-dose compared with a three-dose schedule. One trial with a clinical outcome found no persistent HPV infections occurred after either two or three doses. In non-randomised comparisons, GMC were non-inferior or superior in adolescent girls receiving the two-dose schedule compared with women receiving the three-dose schedule for at least 21months after vaccination. By February 2017, 23 low and middle income and 25 high income countries had adopted a two-dose HPV vaccination schedule. A two-dose HPV vaccine schedule provides satisfactory immunological outcomes in adolescent girls, but uptake globally is limited, particularly in countries with the highest burden of cervical cancer.
[Mh] Termos MeSH primário: Esquemas de Imunização
Vacinas contra Papillomavirus/administração & dosagem
Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antivirais/biossíntese
Ensaios Clínicos como Assunto
Feminino
Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18/administração & dosagem
Seres Humanos
Papillomaviridae/imunologia
Infecções por Papillomavirus/prevenção & controle
Neoplasias do Colo do Útero/prevenção & controle
Vacinação
Potência de Vacina
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18); 0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  9 / 69732 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29382836
[Au] Autor:Füzik T; Formanová P; Ruzek D; Yoshii K; Niedrig M; Plevka P
[Ad] Endereço:Structural Virology, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500, Brno, Czech Republic.
[Ti] Título:Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody.
[So] Source:Nat Commun;9(1):436, 2018 01 30.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tick-borne encephalitis virus (TBEV) causes 13,000 cases of human meningitis and encephalitis annually. However, the structure of the TBEV virion and its interactions with antibodies are unknown. Here, we present cryo-EM structures of the native TBEV virion and its complex with Fab fragments of neutralizing antibody 19/1786. Flavivirus genome delivery depends on membrane fusion that is triggered at low pH. The virion structure indicates that the repulsive interactions of histidine side chains, which become protonated at low pH, may contribute to the disruption of heterotetramers of the TBEV envelope and membrane proteins and induce detachment of the envelope protein ectodomains from the virus membrane. The Fab fragments bind to 120 out of the 180 envelope glycoproteins of the TBEV virion. Unlike most of the previously studied flavivirus-neutralizing antibodies, the Fab fragments do not lock the E-proteins in the native-like arrangement, but interfere with the process of virus-induced membrane fusion.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/química
Anticorpos Antivirais/química
Vírus da Encefalite Transmitidos por Carrapatos/ultraestrutura
Fragmentos Fab das Imunoglobulinas/química
Proteínas Virais/química
Vírion/ultraestrutura
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/biossíntese
Anticorpos Antivirais/biossíntese
Linhagem Celular Tumoral
Microscopia Crioeletrônica
Vírus da Encefalite Transmitidos por Carrapatos/genética
Vírus da Encefalite Transmitidos por Carrapatos/metabolismo
Expressão Gênica
Seres Humanos
Concentração de Íons de Hidrogênio
Fragmentos Fab das Imunoglobulinas/biossíntese
Fusão de Membrana/genética
Neurônios/patologia
Neurônios/virologia
Domínios Proteicos
Multimerização Proteica
Proteínas Virais/genética
Proteínas Virais/metabolismo
Vírion/genética
Vírion/metabolismo
Internalização do Vírus
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Immunoglobulin Fab Fragments); 0 (Viral Proteins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-018-02882-0


  10 / 69732 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954299
[Au] Autor:Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group
[Ad] Endereço:Roche Molecular Diagnostics, Pleasanton, CA; National Cancer Institute, National Institutes of Health, Bethesda, MD; HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; Agencia Costarricense de Investigaciones Biomédicas (ACI
[Ti] Título:Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods: We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Results: Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. Conclusions: At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group.
[Mh] Termos MeSH primário: Papillomavirus Humano 16/imunologia
Papillomavirus Humano 18/imunologia
Vacinas contra Papillomavirus/administração & dosagem
Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Colo do Útero/virologia
DNA Viral/genética
Feminino
Papillomavirus Humano 16/genética
Papillomavirus Humano 18/genética
Seres Humanos
Infecções por Papillomavirus/imunologia
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/virologia
Doenças do Colo do Útero/imunologia
Doenças do Colo do Útero/prevenção & controle
Doenças do Colo do Útero/virologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (DNA, Viral); 0 (Papillomavirus Vaccines); 0 (human papillomavirus vaccine, L1 type 16, 18)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx158



página 1 de 6974 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde